Michael Roberts
Hematology & Oncology · Phoenix, AZNPI 1932159357
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (38.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 41 manufacturers reported payments, led by Lilly USA, LLC at 58.9% of the total. Reporting peaked in 2022 at $6,167 and has fallen 75.7% since, to $1,497 in 2023.
Across 261 payments — averaging $49.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$8K
- Adaptive Biotechnologies Corporation$1K
- Sanofi$484
- Merck$398
- Pfizer$373
- Seagen Inc.$296
- plus $3K from 35 others
Across 10 payments — averaging $2595.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$12K
- Seagen Inc.$11K
- Genentech, Inc.$3K
What the payments were for
- Consulting fees$3,81330%
- Speaking & faculty fees$4,98139%
- Food & beverage$3,77629%
- Education$2442%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 12 | $7,546 |
| Adaptive Biotechnologies Corporation | 1 | $1,000 |
| Sanofi | 5 | $484 |
| Merck | 31 | $398 |
| Pfizer | 34 | $373 |
| Seagen Inc. | 6 | $296 |
| E.r. Squibb & Sons, L.L.C. | 34 | $286 |
| Sun Pharmaceutical Industries Inc. | 7 | $279 |
| Novartis | 21 | $238 |
| Eisai Inc. | 13 | $205 |
| Amgen | 9 | $175 |
| Genentech USA, Inc. | 11 | $150 |
| Boehringer Ingelheim | 8 | $141 |
| Bristol Myers Squibb | 5 | $109 |
| EMD Serono, Inc. | 6 | $104 |
| Astellas Pharma US Inc | 3 | $90 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $84 |
| Gilead(2 entities) | 6 | $75 |
| Incyte Corporation | 5 | $74 |
| Array Biopharma Inc | 4 | $65 |
| AstraZeneca | 4 | $59 |
| Exelixis Inc. | 3 | $57 |
| AbbVie | 3 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
| Lexicon Pharmaceuticals, Inc. | 2 | $42 |
| Abiomed | 1 | $42 |
| Dendreon Pharmaceuticals LLC | 2 | $34 |
| Johnson & Johnson | 2 | $31 |
| Secura Bio, Inc. | 2 | $26 |
| AMAG Pharmaceuticals, Inc. | 2 | $25 |
| Partner Therapeutics, Inc. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Bayer | 1 | $19 |
| Apo-pharma USA, Inc. | 1 | $18 |
| Aurobindo Pharma USA, Inc. | 1 | $14 |
| Mylan Institutional Inc. | 1 | $13 |
| Verastem, Inc. | 1 | $13 |
| Clovis Oncology, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,814 in reported general payments places this provider in the 60th percentile of 261 hematology & oncology providers in Arizona.
Other hematology & oncology in Phoenix
- Javier MunozPhoenix$638K
- Mazen KhattabPhoenix$186K
- Robert GalamagaPhoenix$168K
- Panayiotis SavvidesPhoenix$153K
- Robert YooPhoenix$44K
- Sunil TulpulePhoenix$36K
- Tania CortasPhoenix$33K
- Mahesh SeetharamPhoenix$30K
- Boo Ghee LowPhoenix$25K
- Sujith KalmadiChandler$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.